DOCSLIB.ORG

Nonmonotonic Dose Responses As They Apply to Estrogen, Androgen, and Thyroid Pathways and EPA Testing and Assessment Procedures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nonmonotonic Dose Responses As They Apply to Estrogen, Androgen, and Thyroid Pathways and EPA Testing and Assessment Procedures Draft Deliberative – Do NOT Cite, Quote, or Distribute State of the Science: Nonmonotonic Dose Responses V7 State of the Science Evaluation: Nonmonotonic Dose Responses as They Apply to Estrogen, Androgen, and Thyroid Pathways and EPA Testing and Assessment Procedures U.S. Environmental Protection Agency Jointly developed by: Office of Research and Development Office of Science Policy National Health and Environmental Effects Research Laboratory National Center for Environmental Assessment National Center for Computational Toxicology Office of Chemical Safety and Pollution Prevention Office of Pesticide Programs Office of Pollution Prevention and Toxics Office of Science Coordination and Policy June 2013 1 | Page Draft Deliberative – Do NOT Cite, Quote, or Distribute State of the Science: Nonmonotonic Dose Responses V7 Table of Contents Foreward ................................................................................................................................................. 9 Executive Summary ............................................................................................................................... 10 1. Introduction .................................................................................................................................. 20 1.1 Background ............................................................................................................................ 21 1.2 Scope of the Current Evaluation ............................................................................................. 27 1.3 Central Scientific Questions .................................................................................................... 28 2. General Biological Concepts and Statistical Considerations for NMDR ............................................ 28 2.1 Pharmacokinetic Processes .................................................................................................... 28 2.2 Modes of Action and Adverse Outcome Pathways.................................................................. 29 2.3 Determinants of Nonmonotonic Dose-Response .................................................................... 31 2.4 The Hypothalamic-pituitary-gonadal and Hypothalamic-pituitary-thyroid Axes ...................... 34 2.5 Statistical Issues and Experimental Design .............................................................................. 40 3. NMDRs from in vitro Studies .......................................................................................................... 42 4. NMDRs from in vivo Studies ........................................................................................................... 55 4.1 Aquatic Models ...................................................................................................................... 55 4.1.1 Literature Search and Analysis, Aquatic Species ............................................................ 56 4.1.2 NMDRs in the Estrogen Hormone System in Aquatic Species ........................................ 62 4.1.2.1 Estrogen Receptor Agonists ........................................................................................ 62 4.1.2.2 Selective Estrogen Receptor Modulator (Tamoxifen) .................................................. 64 4.1.3 NMDRs in the Androgen Hormone Pathway in Aquatic Species .................................... 64 4.1.3.1 Androgens .................................................................................................................. 64 4.1.3.2 Androgen Receptor Antagonists ................................................................................. 69 4.1.3.3 Steroid Synthesis Inhibitors......................................................................................... 70 4.1.3.4 Role of Compensatory Processes in NMDR – Examples from Fish Time-Course Studies with Three EDCs ........................................................................................................................ 73 4.1.4 NMDRs in the Thyroid Hormone Pathway in Aquatic Species ........................................ 79 4.1.4.1 Fish ............................................................................................................................. 79 4.1.4.2 Amphibians ................................................................................................................ 82 4.2 Mammalian Models ............................................................................................................... 83 4.2.1 Literature Search and Selection Strategy for E and A Pathways ..................................... 83 4.2.1.1 Specific Considerations in Reviewing the Literature on E and A ................................... 85 4.2.2 Estrogen Hormone System ........................................................................................... 92 4.2.2.1 Ethinyl Estradiol (EE2) [A.1.a] ...................................................................................... 94 4.2.2.2 17β Estradiol (E2) [A.1.b] ............................................................................................ 96 4.2.2.3 Diethylstilbestrol (DES) [A.1.c] .................................................................................... 96 4.2.2.4 Genistein [A.1.d] ......................................................................................................... 97 4.2.2.5 Bisphenol A [A.1.k] ..................................................................................................... 99 4.2.2.6 Selective Estrogen Receptor Modulators (SERMs) [A.2]............................................. 101 4.2.2.7 Tamoxifen [A.2.b] ..................................................................................................... 101 4.2.2.8 Aromatase Inhibitors (AI: block androgen to estrogen synthesis) [A.3] ...................... 102 4.2.2.9 Exemestane [A.3.b] ................................................................................................... 102 4.2.3 Androgen Hormone System [B] .................................................................................. 102 4.2.3.1 Vinclozolin [B.1.b] ..................................................................................................... 106 4.2.3.2 Procymidone [B.1.c].................................................................................................. 106 4.2.3.3 Phthalates [B.2] ........................................................................................................ 107 4.2.3.4 Semicarbazide [B.4] .................................................................................................. 115 4.2.3.5 Multiple Molecular Initiating Events [B.5] ................................................................. 115 2 | Page Draft Deliberative – Do NOT Cite, Quote, or Distribute State of the Science: Nonmonotonic Dose Responses V7 4.2.3.6 Androgen Receptor Agonists [B.6] ............................................................................ 116 4.2.3.7 Selective Androgen Receptor Modulators (SARMS) [B.7] .......................................... 118 4.2.4 Thyroid ....................................................................................................................... 119 4.2.4.1 Environmental Contaminants and Thyroid Disruption ............................................... 120 4.2.4.2 Literature Search and Analysis .................................................................................. 121 4.2.4.3 Review of Three Major Targets for Nonmonotonic Thyroid Pathway Disruption ....... 122 4.2.4.4 Results of Literature Analysis .................................................................................... 129 4.2.4.5 Conclusions for Thyroid Studies ................................................................................ 133 4.3 Human Studies and Epidemiology ........................................................................................ 136 4.3.1 Context for Human Studies in this Review .................................................................. 136 4.3.2 Interpreting Epidemiological Evidence ........................................................................ 136 4.3.2.1 Multiple Exposures (Combined or in Sequence) ........................................................ 137 4.3.2.2 Exposure Assessment ............................................................................................... 137 4.3.3 Moving Forward – Converging Evidence ..................................................................... 138 4.3.4 Summary .................................................................................................................... 139 5. Conclusions ................................................................................................................................. 139 5.1 General Conclusions ............................................................................................................. 139 5.1.1 Overall Conclusions: Estrogen, Androgen, and Thyroid ............................................... 142 5.2 Central Scientific Questions and Answers ............................................................................. 144 5.2.1 Do nonmonotonic dose responses (NMDRs) exist for chemicals and if so under what conditions do they occur? .......................................................................................... 144 5.2.2 Do NMDRs capture adverse effects that are not captured using our current chemical testing strategies (i.e., false negatives)?.....................................................................
Load more

Recommended publications
  • WADA Technical Letter – TL07 ANDARINE
    WADA Technical Letter – TL07 Document Number: TL07 Version Number: 3.0 Written by: WADA Science Approved by: WADA Executive Committee Reviewed by: WADA Laboratory Expert Group Date: 21 December 2020 Effective Date: 1 January 2021 ANDARINE - FLUTAMIDE 1.0 Introduction WADA wishes to draw the attention of the Laboratories to the following observations and instructions on the analysis and reporting of SARM S4 (Andarine) Metabolites O-dephenylandarine and O- dephenylandarine glucuronide. The andarine Metabolites O-dephenylandarine and of O-dephenylandarine glucuronide may also be present in a Sample as a Metabolite of the anti-androgen Flutamide (Drogenil®, Eulexin®, Euflex®, Flutamin®, Flugere®), used primarily in the treatment of prostate cancer [1]. Since flutamide is not a Prohibited Substance in sports, the Laboratories shall not report an Adverse Analytical Finding (AAF) for andarine based on the monitoring of O-dephenylandarine [2]. Figure 1. Proposed metabolic pathway of flutamide and andarine (adapted from Perrenoud et al. [1]). 2.0 Analysis and Reporting Requirements Report the result as an AAF for andarine only when the presence of andarine (parent compound), and/or its glucuronic acid conjugate, and/or its deacetylated and/or hydroxylated Metabolites, and/or its bishydroxylated product [2] are confirmed in the Sample (regardless of the presence of flutamide and/or its Metabolite 2-hydroxyflutamide); [Comment: Laboratories shall not report an AAF for andarine based only on the presence of O- dephenylandarine.] 3.0 References [1] Perrenoud L. et al. Risk of false positive results to SARM S4 in case of therapeutic use of antineoplastic/antiandrogen drug containing flutamide: a case study.
    [Show full text]
  • Evaluation of Tebuconazole, Triclosan, Methylparaben and Ethylparaben According to the Danish Proposal for Criteria for Endocrine Disrupters
    Downloaded from orbit.dtu.dk on: Sep 26, 2021 Evaluation of tebuconazole, triclosan, methylparaben and ethylparaben according to the Danish proposal for criteria for endocrine disrupters Hass, Ulla; Christiansen, Sofie; Petersen, Marta Axelstad; Boberg, Julie; Andersson, Anna-Maria ; Skakkebæk, Niels Erik ; Bay, Katrine ; Holbech, Henrik ; Lund Kinnberg, Karin ; Bjerregaard, Poul Publication date: 2012 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Hass, U., Christiansen, S., Petersen, M. A., Boberg, J., Andersson, A-M., Skakkebæk, N. E., Bay, K., Holbech, H., Lund Kinnberg, K., & Bjerregaard, P. (2012). Evaluation of tebuconazole, triclosan, methylparaben and ethylparaben according to the Danish proposal for criteria for endocrine disrupters. Danish Centre on Endocrine Disrupters. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will
    [Show full text]
  • Aromasin (Exemestane)
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------ADVERSE REACTIONS------------------------------­ These highlights do not include all the information needed to use • Early breast cancer: Adverse reactions occurring in ≥10% of patients in AROMASIN safely and effectively. See full prescribing information for any treatment group (AROMASIN vs. tamoxifen) were hot flushes AROMASIN. (21.2% vs. 19.9%), fatigue (16.1% vs. 14.7%), arthralgia (14.6% vs. 8.6%), headache (13.1% vs. 10.8%), insomnia (12.4% vs. 8.9%), and AROMASIN® (exemestane) tablets, for oral use increased sweating (11.8% vs. 10.4%). Discontinuation rates due to AEs Initial U.S. Approval: 1999 were similar between AROMASIN and tamoxifen (6.3% vs. 5.1%). Incidences of cardiac ischemic events (myocardial infarction, angina, ----------------------------INDICATIONS AND USAGE--------------------------- and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%. AROMASIN is an aromatase inhibitor indicated for: Incidence of cardiac failure: AROMASIN 0.4%, tamoxifen 0.3% (6, • adjuvant treatment of postmenopausal women with estrogen-receptor 6.1). positive early breast cancer who have received two to three years of • Advanced breast cancer: Most common adverse reactions were mild to tamoxifen and are switched to AROMASIN for completion of a total of moderate and included hot flushes (13% vs. 5%), nausea (9% vs. 5%), five consecutive years of adjuvant hormonal therapy (14.1). fatigue (8% vs. 10%), increased sweating (4% vs. 8%), and increased • treatment of advanced breast cancer in postmenopausal women whose appetite (3% vs. 6%) for AROMASIN and megestrol acetate, disease has progressed following tamoxifen therapy (14.2). respectively (6, 6.1). ----------------------DOSAGE AND ADMINISTRATION----------------------- To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at Recommended Dose: One 25 mg tablet once daily after a meal (2.1).
    [Show full text]
  • COMBINED LIST of Particularly Hazardous Substances
    COMBINED LIST of Particularly Hazardous Substances revised 2/4/2021 IARC list 1 are Carcinogenic to humans list compiled by Hector Acuna, UCSB IARC list Group 2A Probably carcinogenic to humans IARC list Group 2B Possibly carcinogenic to humans If any of the chemicals listed below are used in your research then complete a Standard Operating Procedure (SOP) for the product as described in the Chemical Hygiene Plan. Prop 65 known to cause cancer or reproductive toxicity Material(s) not on the list does not preclude one from completing an SOP. Other extremely toxic chemicals KNOWN Carcinogens from National Toxicology Program (NTP) or other high hazards will require the development of an SOP. Red= added in 2020 or status change Reasonably Anticipated NTP EPA Haz list COMBINED LIST of Particularly Hazardous Substances CAS Source from where the material is listed. 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide Acutely Toxic Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- Acutely Toxic 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) Prop 65 KNOWN Carcinogens NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) IARC list Group 2A Reasonably Anticipated NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) Prop 65 1-(o-Chlorophenyl)thiourea Acutely Toxic 1,1,1,2-Tetrachloroethane IARC list Group 2B 1,1,2,2-Tetrachloroethane Prop 65 IARC list Group 2B 1,1-Dichloro-2,2-bis(p -chloropheny)ethylene (DDE) Prop 65 1,1-Dichloroethane
    [Show full text]
  • Critical Role of Oxidative Stress in Estrogen-Induced Carcinogenesis
    Critical role of oxidative stress in estrogen-induced carcinogenesis Hari K. Bhat*†, Gloria Calaf‡, Tom K. Hei*‡, Theresa Loya§, and Jaydutt V. Vadgama¶ *Department of Environmental Health Sciences, Mailman School of Public Health, 60 Haven Avenue-B1, Columbia University, New York, NY 10032; ‡Center for Radiological Research, Columbia University, New York, NY 10032; and Departments of §Pathology and ¶Medicine, Charles Drew University, Los Angeles, CA 90059 Communicated by Donald C. Malins, Pacific Northwest Research Institute, Seattle, WA, December 27, 2002 (received for review August 22, 2002) Mechanisms of estrogen-induced tumorigenesis in the target quinones generates oxidative stress and potentially harmful free organ are not well understood. It has been suggested that oxida- radicals that are postulated to be required for the carcinogenic tive stress resulting from metabolic activation of carcinogenic process, and analogous to the metabolic activation of hydrocar- estrogens plays a critical role in estrogen-induced carcinogenesis. bons and other nonsteroidal estrogen carcinogens (9, 19–22). We We tested this hypothesis by using an estrogen-induced hamster have investigated the role of oxidative stress in estrogen carci- renal tumor model, a well established animal model of hormonal nogenesis by using a well established hamster renal tumor model carcinogenesis. Hamsters were implanted with 17␤-estradiol (␤E2), that shares several characteristics with human breast and uterine 17␣-estradiol (␣E2), 17␣-ethinylestradiol (␣EE), menadione, a com- cancers, pointing to a common mechanistic origin (6, 9, 23). bination of ␣E2 and ␣EE, or a combination of ␣EE and menadione Different estrogens used in the present study differ in their for 7 months.
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT NAME DHEA (Prasterone) (Micronized) PRODUCT CODE 0733 SUPPLIER MEDISCA Inc. Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 USES Adjuvant; Androgen SECTION 2: HAZARDS IDENTIFICATION GHS CLASSIFICATION Toxic to Reproduction (Category 2) PICTOGRAM SIGNAL WORD Warning HAZARD STATEMENT(S) Reproductive effector, prohormone. Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. Causes serious eye irritation. Causes skin and respiratory irritation. Very toxic to aquatic life with long lasting effects. AUSTRALIA-ONLY HAZARDS Not Applicable. PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dusts or mists. Do not eat, drink or smoke when using this product. Avoid contact during pregnancy/while nursing. Wear protective gloves, protective clothing, eye protection, face protection. Avoid release to the environment. Response IF ON SKIN (HAIR): Wash with plenty of water.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Quantity Does Matter. Juvenile Hormone and the Onset of Vitellogenesis in the German Cockroach J
    Insect Biochemistry and Molecular Biology 33 (2003) 1219–1225 www.elsevier.com/locate/ibmb Quantity does matter. Juvenile hormone and the onset of vitellogenesis in the German cockroach J. Cruz, D. Martı´n, N. Pascual, J.L. Maestro, M.D. Piulachs, X. Belle´s ∗ Department of Physiology and Molecular Biodiversity, Institut de Biologia Molecular de Barcelona (CSIC), Jordi Girona 18, 08034 Barcelona, Spain Received 7 February 2003; received in revised form 18 May 2003; accepted 28 June 2003 Abstract We aimed to elucidate why cockroaches do not produce vitellogenin in immature stages, by studying the appearance of vitellog- enin mRNA in larvae of Blattella germanica. Treatment of female larvae in any of the last three instars with 1 µg of juvenile hormone (JH) III induces vitellogenin gene transcription, which indicates that the fat body is competent to transcribe vitellogenin at least from the antepenultimate instar larvae. In untreated females, vitellogenin production starts on day 1 after the imaginal molt, when corpora allata begin to synthesize JH III at rates doubling the maximal of larval stages. This coincidence suggests that the female reaches the threshold of JH production necessary to induce vitellogenin synthesis on day 1 of adult life. These data lead to postulate that larvae do not synthesize vitellogenin simply because they do not produce enough JH, not because their fat body is incompetent. 2003 Elsevier Ltd. All rights reserved. Keywords: Vitellogenin; Juvenile hormone; German cockroach; Blattella germanica; Reproduction; Metamorphosis; Ecdysteroids 1. Introduction most insect groups, which start vitellogenesis after the imaginal molt. Why, then, do immature insects not pro- In practically all insect species, vitellogenesis and duce vitellogenin? It is because the genes coding for vit- oocyte growth are restricted to the adult stage.
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • Vargas KEA, Et Al. Hepatotoxicity Associated with Methylstenbolone and Copyright© Vargas KEA, Et Al
    1. Medical Journal of Clinical Trials & Case Studies ISSN: 2578-4838 Hepatotoxicity Associated with Methylstenbolone and Stanozolol Abuse Vargas KEA*, Guaraná TA, Biccas BN, Agoglia LV, Carvalho ACG, Case Report Gismondi R and Esberard EBC Volume 2 Issue 5 Received Date: July 27, 2018 Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Published Date: September 03, 2018 Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense DOI: 10.23880/mjccs-16000176 University, Rio de Janeiro, Brazil *Corresponding author: Vargas Karen Elizabeth Arce, Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense University, Rio de Janeiro, Ernani do Amaral Peixoto Avenue, 935. Ap.901 / Cep.24020043, Brazil, Tel: 005521981584624; Email: [email protected] Abstract Background & Objectives: Drug hepatotoxicity is a major cause of liver disease. Many drugs are well known to induce liver damage. Some toxic products, like anabolic androgenic steroids, that are pharmaceutical preparations since they contain pharmaceutically active substance, are available as nutritional supplements. Many patients are used to consume these like dietary stuff. Methods: We introduce a case series of two patients who developed hepatic damage after the consumption of anabolic- androgenic steroids, accompanied by a detailed bibliographic research on this topic. Results: We present two young men who developed significant liver damage, both with hyperbilirubinemia pattern after consumption of anabolic-androgenic steroids. This was associated with considerable morbidity, although both recovered without liver transplantation. The two anabolic-androgenic steroids were being marketed as dietary supplements. Conclusions: Although not well controlled substances in Brazil, anabolic-androgenic steroids are cause of severe hepatotoxicity.
    [Show full text]
  • Toxicological Profile for Bisphenol A
    TT TOXICOLOGICAL PROFILE FOR BISPHENOL A September 2009 Integrated Risk Assessment Branch Office of Environmental Health Hazard Assessment California Environmental Protection Agency Toxicological Profile for Bisphenol A September 2009 Prepared by Office of Environmental Health Hazard Assessment Prepared for Ocean Protection Council Under an Interagency Agreement, Number 07-055, with the State Coastal Conservancy LIST OF CONTRIBUTORS Authors Jim Carlisle, D.V.M., Ph.D., Senior Toxicologist, Integrated Risk Assessment Branch Dave Chan, D. Env., Staff Toxicologist, Integrated Risk Assessment Branch Mari Golub, Ph.D., Staff Toxicologist, Reproductive and Cancer Hazard Assessment Branch Sarah Henkel, Ph.D., California Sea Grant Fellow, California Ocean Science Trust Page Painter, M.D., Ph.D., Senior Toxicologist, Integrated Risk Assessment Branch K. Lily Wu, Ph.D., Associate Toxicologist, Reproductive and Cancer Hazard Assessment Branch Reviewers David Siegel, Ph.D., Chief, Integrated Risk Assessment Branch i Table of Contents Executive Summary ................................................................................................................................ iv Use and Exposure ............................................................................................................................... iv Environmental Occurrence ................................................................................................................. iv Effects on Aquatic Life ......................................................................................................................
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]